UsAgainstAlzheimer's Blog

Stay up to date on the latest from UsAgainstAlzheimer's on our blog. Read about what our team is working on, the latest advancements in research, and what you can do to join the fight.

Working with UsAgainstAlzheimer’s and Voices of Alzheimer’s, Jay Reinstein takes you with him to better understand a day in the life of someone living with Alzheimer’s.

View Jay's Journal Women of UsAgainstAlzheimer's.

November 07, 2023

Statement on Dr. Monica M. Bertagnolli’s Confirmation as Director of the National Institutes of Health

Today, UsAgainstAlzheimer’s celebrated the confirmation of Dr. Monica M. Bertagnolli as the Director of the National Institutes of Health (NIH).
Definition of Brain Health and  Outcomes
October 30, 2023

Roundtable Brief #3 Defining Brain Health

What is brain health, exactly, and why should business leaders care?
October 30, 2023

Roundtable Brief #1: The Case for Private Sector Engagement in Brain Health

DOWNLOAD BRIEF About the Business Collaborative for Brain Health The Business Collaborative for Brain Health is a group of private sector partners developing innovative solutions to optimize cognitive health throughout the lifespan. The Collaborative’s mission is to build brain health capital by advancing measurably effective brain healthy workplaces, communities, and product and service innovations. The Collaborative’s premise is that promoting brain health is essential to growing the U.S. our economy, strengthening national security, and improving health and well-being. Our nation relies on brainpower more than ever before to solve critical challenges and drive innovation. Profound demographic and technological shifts have
October 25, 2023

Eating for the Future: Women's Midlife Diets Shape Later-Life Brain Health and Memory

Plant-based diet promotes later life brain health in women.
January 04, 2023

30 Years On, Are We Winning the Fight Against Alzheimer’s?

Lecanemab, Donanemab, Drug-Free Strategies Emerge as New Weapons Against Dementia By Suzanne Leigh UC San Francisco experts say that we have reached a pivotal point in Alzheimer’s disease research, 30 years after the first pharmaceutical came to market. On Jan. 6, 2023, the Food and Drug Administration is expected to give accelerated approval of lecanemab – one of the first drugs to attract widespread enthusiasm among neurologists, after showing positive phase 3 results in slowing the progression of early-stage disease. The UCSF-tested drug is a monoclonal antibody, a lab-made protein, that targets amyloid plaques that accumulate between neurons and disrupt